Entera Bio Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENTX Nasdaq 2836 enterabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Entera Bio Ltd.

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 - Apr 14th, 2026 6:45 am
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds - Apr 2nd, 2026 6:45 am
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates - Mar 27th, 2026 2:05 pm
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - Mar 4th, 2026 6:30 am
Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board - Feb 27th, 2026 5:00 am
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference - Feb 26th, 2026 6:00 am
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation - Feb 17th, 2026 6:42 pm
Entera Bio Announces Open Market Purchases of Company Stock by Board Members - Feb 11th, 2026 7:00 am
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones - Feb 9th, 2026 6:50 am
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Feb 6th, 2026 9:02 am
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism - Feb 4th, 2026 6:00 am
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook - Jan 21st, 2026 6:30 am
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation - Dec 31st, 2025 5:51 am
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation - Dec 23rd, 2025 6:30 am
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) - Dec 22nd, 2025 6:30 am
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference - Nov 18th, 2025 6:00 am
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates - Nov 14th, 2025 2:05 pm
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women - Oct 23rd, 2025 6:50 am
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting - Oct 16th, 2025 6:45 am
Individual investors are Entera Bio Ltd.'s (NASDAQ:ENTX) biggest owners and were rewarded after market cap rose by US$34m last week - Oct 11th, 2025 6:33 am